Misplaced Pages

Cediranib: Difference between revisions

Article snapshot taken from Wikipedia with creative commons attribution-sharealike license. Give it a read and then ask your questions in the chat. We can research this topic together.
Browse history interactively
Page 1
Page 2
← Previous editContent deleted Content addedVisualWikitext
Revision as of 18:15, 10 September 2011 editPotatoBot (talk | contribs)Bots51,239 editsm Stub sorting and placement of stub template(s): antineoplastic-drug-stub. See approval. Report errors and suggestions at User talk:PotatoBot.← Previous edit Latest revision as of 19:21, 20 December 2023 edit undoJJMC89 bot III (talk | contribs)Bots, Administrators3,706,216 editsm Moving Category:AstraZeneca brands to Category:Drugs developed by AstraZeneca per Misplaced Pages:Categories for discussion/Log/2023 December 9#Category:AstraZeneca brands 
(60 intermediate revisions by 38 users not shown)
Line 1: Line 1:
{{Short description|Chemical compound}}
{{Drugbox {{Drugbox
| Verifiedfields = changed
⚫ | verifiedrevid = 447885676
| Watchedfields = changed
⚫ | verifiedrevid = 449572361
| IUPAC_name = 4--6-methoxy-7-quinazoline | IUPAC_name = 4--6-methoxy-7-quinazoline
| image = AZD2171.svg | image = Cediranib.svg

<!--Clinical data--> <!--Clinical data-->
| tradename = | tradename =
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X --> | pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US = <!-- A / B / C / D / X --> | pregnancy_US = <!-- A / B / C / D / X -->
| pregnancy_category = | pregnancy_category =
| legal_AU = <!-- Unscheduled / S2 / S3 / S4 / S8 --> | legal_AU = <!-- Unscheduled / S2 / S3 / S4 / S8 -->
| legal_CA = <!-- / Schedule I, II, III, IV, V, VI, VII, VIII --> | legal_CA = <!-- / Schedule I, II, III, IV, V, VI, VII, VIII -->
| legal_UK = <!-- GSL / P / POM / CD / Class A, B, C --> | legal_UK = <!-- GSL / P / POM / CD / Class A, B, C -->
| legal_US = <!-- OTC / Rx-only / Schedule I, II, III, IV, V --> | legal_US = <!-- OTC / Rx-only / Schedule I, II, III, IV, V -->
| legal_status = | legal_status =
| routes_of_administration = Oral | routes_of_administration = Oral

<!--Pharmacokinetic data--> <!--Pharmacokinetic data-->
| bioavailability = | bioavailability =
| protein_bound = | protein_bound =
| metabolism = | metabolism =
| elimination_half-life = 12 to 35 hours | elimination_half-life = 12 to 35 hours
| excretion = | excretion =

<!--Identifiers--> <!--Identifiers-->
| IUPHAR_ligand = 5664
| CASNo_Ref = {{cascite|correct|CAS}} | CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 288383-20-0 | CAS_number = 288383-20-0
| ATC_prefix = none | ATC_prefix = L01
| ATC_suffix = | ATC_suffix = EK02
⚫ | PubChem =
| DrugBank_Ref = {{drugbankcite|correct|drugbank}} | DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank = | DrugBank =
| UNII_Ref = {{fdacite|correct|FDA}} | UNII_Ref = {{fdacite|correct|FDA}}
| UNII = NQU9IPY4K9 | UNII = NQU9IPY4K9
⚫ | PubChem = 9933475

| ChEMBL_Ref = {{ebicite|changed|EBI}}
| ChEMBL = 491473
| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}
| ChemSpiderID = 8109103
| KEGG = D08881
| StdInChI_Ref = {{stdinchicite|changed|chemspider}}
| StdInChI = 1S/C25H27FN4O3/c1-16-12-17-19(29-16)6-7-21(24(17)26)33-25-18-13-22(31-2)23(14-20(18)27-15-28-25)32-11-5-10-30-8-3-4-9-30/h6-7,12-15,29H,3-5,8-11H2,1-2H3
| StdInChIKey_Ref = {{stdinchicite|changed|chemspider}}
| StdInChIKey = XXJWYDDUDKYVKI-UHFFFAOYSA-N
<!--Chemical data--> <!--Chemical data-->
| C=25 | H=27 | F=1 | N=4 | O=3 | C=25 | H=27 | F=1 | N=4 | O=3
| smiles = COc4cc3c(Oc2ccc1c(C)cc1c2F)ncnc3cc4OCCCN5CCCC5
| molecular_weight = 450.505 g/mol
| smiles = Cc4nc5ccc(Oc3ncnc2cc(OCCCN1CCCC1)c(OC)cc23)c(F)c5c4
}} }}
'''Cediranib''' (tentative trade name '''Recentin'''), also known as AZD2171, is a potent ] of ] (VEGF) receptor ]s.<ref name="pmid15899831">{{cite journal |author=Wedge SR, Kendrew J, Hennequin LF, ''et al.'' |title=AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer |journal=Cancer Res. |volume=65 |issue=10 |pages=4389–400 |year=2005 |month=May |pmid=15899831 |doi=10.1158/0008-5472.CAN-04-4409 |url=http://cancerres.aacrjournals.org/cgi/pmidlookup?view=long&pmid=15899831}}</ref><ref name="pmid19091548">{{cite journal |author=Goss G, Shepherd FA, Laurie S, ''et al.'' |title=A phase I and pharmacokinetic study of daily oral cediranib, an inhibitor of vascular endothelial growth factor tyrosine kinases, in combination with cisplatin and gemcitabine in patients with advanced non-small cell lung cancer: A study of the National Cancer Institute of Canada Clinical Trials Group |journal=Eur. J. Cancer |volume= 45|issue= 5|pages= 782|year=2008 |month=December |pmid=19091548 |doi=10.1016/j.ejca.2008.10.022 |url=http://linkinghub.elsevier.com/retrieve/pii/S0959-8049(08)00868-X}}</ref><ref name="pmid18520296">{{cite journal |author=Nikolinakos P, Heymach JV |title=The tyrosine kinase inhibitor cediranib for non-small cell lung cancer and other thoracic malignancies |journal=J Thorac Oncol |volume=3 |issue=6 Suppl 2 |pages=S131–4 |year=2008 |month=June |pmid=18520296 |doi=10.1097/JTO.0b013e318174e910 |url=http://meta.wkhealth.com/pt/pt-core/template-journal/lwwgateway/media/landingpage.htm?doi=10.1097/JTO.0b013e318174e910}}</ref> '''Cediranib''' (AZD-2171; tentative trade name '''Recentin''') is a potent ] of ] (VEGF) receptor ]s.<ref name="pmid15899831">{{cite journal | vauthors = Wedge SR, Kendrew J, Hennequin LF, Valentine PJ, Barry ST, Brave SR, Smith NR, James NH, Dukes M, Curwen JO, Chester R, Jackson JA, Boffey SJ, Kilburn LL, Barnett S, Richmond GH, Wadsworth PF, Walker M, Bigley AL, Taylor ST, Cooper L, Beck S, Jürgensmeier JM, Ogilvie DJ | display-authors = 6 | title = AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer | journal = Cancer Research | volume = 65 | issue = 10 | pages = 4389–400 | date = May 2005 | pmid = 15899831 | doi = 10.1158/0008-5472.CAN-04-4409 | doi-access = free }}</ref><ref name="pmid19091548">{{cite journal | vauthors = Goss G, Shepherd FA, Laurie S, Gauthier I, Leighl N, Chen E, Feld R, Powers J, Seymour L | display-authors = 6 | title = A phase I and pharmacokinetic study of daily oral cediranib, an inhibitor of vascular endothelial growth factor tyrosine kinases, in combination with cisplatin and gemcitabine in patients with advanced non-small cell lung cancer: a study of the National Cancer Institute of Canada Clinical Trials Group | journal = European Journal of Cancer | volume = 45 | issue = 5 | pages = 782–8 | date = March 2009 | pmid = 19091548 | doi = 10.1016/j.ejca.2008.10.022 }}</ref><ref name="pmid18520296">{{cite journal | vauthors = Nikolinakos P, Heymach JV | title = The tyrosine kinase inhibitor cediranib for non-small cell lung cancer and other thoracic malignancies | journal = Journal of Thoracic Oncology | volume = 3 | issue = 6 Suppl 2 | pages = S131-4 | date = June 2008 | pmid = 18520296 | doi = 10.1097/JTO.0b013e318174e910 | doi-access = free }}</ref>


It is being developed by ] as a possible anti-cancer chemotherapeutic agent for oral administration. The drug is being developed by ] as a possible anti-cancer chemotherapeutic agent for oral administration.


== Clinical trials ==
Beginning in 2007, it is undergoing ] ]s for the treatment of ] ], ], and ] in adults, as well as tumors of the ] in children. Phase I trials of interactions with other drugs used in cancer treatment are also underway. Beginning in 2007, it underwent ] ]s for the treatment of ] ], ], and ] in adults, as well as tumors of the ] in children. Phase I trials of interactions with other drugs used in cancer treatment were also undertaken.{{cn|date=February 2023}}


On February 27, 2008, AstraZeneca announced that the use of Recentin in non-small cell lung cancer will not progress into phase III after failing to meet its main goal. On February 27, 2008, AstraZeneca announced that the use of cediranib in non-small cell lung cancer will not progress into phase III after failing to meet its main goal. On 8 March 2010, AstraZeneca issued a press-release stating that cediranib had failed Phase III clinical trials for use in first-line metastatic colorectal cancer when it was compared clinically with the market-leader ].<ref>{{cite web|title=AstraZeneca - RECENTIN did not meet primary endpoint in Horizon III study in metastatic colorectal cancer|url=http://www.astrazeneca.com/Media/Press-releases/Article/20100308--RECENTIN-did-not-meet-primary-endpoint-in-Horizon-III|access-date=17 March 2014}}</ref>
In 2016, AstraZeneca completed a phase III trial comparing the efficacy of cediranib alone and cediranib with ] to the efficacy of lomustine alone in patients with recurrent ]. The trial failed to meet its primary endpoint and survival was not extended with cediranib.<ref>{{cite journal | vauthors = Batchelor TT, Mulholland P, Neyns B, Nabors LB, Campone M, Wick A, Mason W, Mikkelsen T, Phuphanich S, Ashby LS, Degroot J, Gattamaneni R, Cher L, Rosenthal M, Payer F, Jürgensmeier JM, Jain RK, Sorensen AG, Xu J, Liu Q, van den Bent M | display-authors = 6 | title = Phase III randomized trial comparing the efficacy of cediranib as monotherapy, and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastoma | journal = Journal of Clinical Oncology | volume = 31 | issue = 26 | pages = 3212–8 | date = September 2013 | pmid = 23940216 | pmc = 4021043 | doi = 10.1200/JCO.2012.47.2464 | authorlink8 = Tom Mikkelsen }}</ref>


==Combination trials==
On 8th March 2010, AstraZeneca issued a press-release stating that Recentin had failed Phase III clinical trials for use in first-line metastatic colorectal cancer when it was compared clinically with the market-leader Avastin.
Findings from a federally funded, NCI-sponsored phase II clinical trial<ref>{{ClinicalTrialsGov|NCT01116648|Cediranib Maleate and Olaparib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Peritoneal Cancer or Recurrent Triple-Negative Breast Cancer}}</ref> presented at the 50th Annual Meeting of the ] (May 30 - June 3, 2014, Chicago, Ill; Abstract No: LBA5500),<ref>{{cite journal | vauthors = Liu JF, Barry WT, Birrer M, Lee JM, Buckanovich RJ, Fleming GF, Rimel B, Buss MK, Nattam S, Hurteau J, Luo W, Quy P, Whalen C, Obermayer L, Lee H, Winer EP, Kohn EC, Ivy SP, Matulonis UA | display-authors = 6 | title = Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study | journal = The Lancet. Oncology | volume = 15 | issue = 11 | pages = 1207–14 | date = October 2014 | pmid = 25218906 | pmc = 4294183 | doi = 10.1016/S1470-2045(14)70391-2 }}</ref> show that the combination of two investigational oral drugs, ], a PARP inhibitor, and cediranib is significantly more active against recurrent, platinum chemotherapy-sensitive disease or ovarian cancer related to mutations in BRCA genes than olaparib alone.<ref>{{Cite web |url=http://oncozine.com/profiles/blogs/combination-of-targeted-drugs-may-significantly-increase-pfs |title=Combination of Targeted Drugs May Significantly Increase Progression-Free Survival in Women with Recurrent Ovarian Cancer, Study Shows - Onco'Zine - The International Oncology Network; June 2, 2014 |access-date=June 12, 2014 |archive-url=https://web.archive.org/web/20150221153623/http://oncozine.com/profiles/blogs/combination-of-targeted-drugs-may-significantly-increase-pfs |archive-date=February 21, 2015 |url-status=dead }}</ref>
⚫ ==References==

⚫ == References ==
{{reflist}} {{reflist}}
http://www.astrazeneca.com/media/latest-press-releases/2010-new/recoentin-horizon?itemId=8748245


==External links== == External links ==
* *


{{Extracellular chemotherapeutic agents}} {{Extracellular chemotherapeutic agents}}
{{Growth factor receptor modulators}}


] ]
] ]
] ]
] ]
] ]
] ]
]

]

{{antineoplastic-drug-stub}}
Cediranib: Difference between revisions Add topic